Concord Asset Management, Llc/Va Bristol Myers Squibb CO Transaction History

Concord Asset Management, Llc/Va

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 06, 2024	SELL	$47.98 - $54.4 $1.22 Million - $1.38 Million	-25,353 Closed	0 $0
Q4 2023 Nov 06, 2024	BUY	$48.48 - $57.85 $472,098 - $563,343	9,738 Added 62.36%	25,353 $1.3 Billion
Q3 2023 Nov 06, 2024	BUY	$57.89 - $64.73 $171,759 - $192,053	2,967 Added 23.46%	15,615 $906 Million
Q2 2023 Nov 06, 2024	BUY	$63.71 - $70.74 $148,444 - $164,824	2,330 Added 22.58%	12,648 $809 Million
Q1 2023 Nov 06, 2024	BUY	$65.71 - $74.53 $454,121 - $515,076	6,911 Added 202.85%	10,318 $715 Million
Q4 2022 Nov 06, 2024	BUY	$68.48 - $81.09 $233,311 - $276,273	3,407 New	3,407 $245 Million

2,457

1.5B

29.6M

32.1M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $118B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Concord Asset Management, Llc/Va, based on Form 13F filings with the SEC.

Stay updated on Concord Asset Management, Llc/Va with notifications on news.